Strong financial performance with 22% revenue growth, achievement of profitability ($2.2M net income), robust free cash flow ($14.3M), raised full-year guidance, record MACI revenue and biopsies, and authorization of $200M share repurchase program reflecting management confidence in sustained growth trajectory.
Articles that tag VCEL but are mainly about other companies.
Listed among leading stem cell therapy companies benefiting from growing demand for regenerative medicine and expanding therapeutic applications
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
